A perceived shortcoming of transgenic rodent mutation assays is the relatively high spontaneous mutant frequencies (MFs) of the bacterial transgenes compared to endogenous genes. This background is dominated by G:CªA:T mutation, frequently in a CpG context, mammalian sites of cytosine methylation. The single A:T target site of the FX174 transgenic mouse reversion assay might avoid this background, yet in vivo mutagenic sensitivity at this site was poor because of background mutation in the recovery bacteria. In order to determine the actual spontaneous MF of the FX174 transgene in the mouse cell, several research tools have been developed: 1) single burst analysis, for distinguishing mouse from bacterial mutation; 2) a transgenic mouse embryonic cell line, PX-2; and 3) a forward mutational assay, which has few CpG sites among its target sites. In this study, single burst analysis was applied to the transgenic cell line for theˆrst time, evaluating the response to UVB irradiation for potential phototoxicity studies. Under appropriate plating conditions, single burst analysis lowered the spontaneous MF10-fold from the original report to 0.17×10 -5 . The MF 72 h after 70 J/m 2 UVB irradiation was 8.3×10 -5 . The characteristic UVB-induced mutant spectrum included À80% G:CªA:T at dipyrimidine sites (primarily TpC dinucleotides) with 13% of these at a single CpG site, and 20% as multiple mutants, tandem and non-tandem. The spontaneous MF per nucleotide, 3×10 -8 , was comparable to that of human disease genes in the germline. When normalized for target number and dose, single burst analysis of the FX174 forward mutational assay produced a UVB-induced MF that was equivalent to that of the cII transgene in mouse cell culture, but a spontaneous MF an order of magnitude lower. The results suggest this cell line is highly sensitive to UVB irradiation.
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Introduction
The FX174 transgenic (Malling) mouse was one of theˆrst transgenic rodents developed for detecting in vivo mutation (1) . The FX174 genome was chosen for its small size (allowing recovery by electroporation), unique sequence (not homologous to mammalian or E. coli genomes), and speciˆcity for a single A:T base pair as a reversion assay (avoiding background from spontaneous deamination of methylated cytosine at CpG sites).
For the lacI transgene, about half of all spontaneous mutations are G:CªA:T transitions and over 80z of these occur within a CpG context (2) . Although fewer mutants have been sequenced, similar spontaneous distributions have been found for the cII (3), lacZ (4) and gpt delta transgenes (5) . The high CpG content of bacterial genes, and the lacI gene in particular, was considered an impediment to sensitivity in the early characterization of transgenic mutation assays (6, 7) , and a new lacI transgenic mouse was created with reduced CpG content (8) . However, reducing the number of CpG sites in the lacI gene did not reduce spontaneous mutant frequencies (MFs), but rather shifted mutation to the remaining CpG sites (9) . The relatively high spontaneous frequencies of transgenic mutation assays compared to endogenous genes are still a perceived disadvantage of these systems (2) .
The FX174 reversion assay is not dominated by mutation at CpG sites since the mutational target is a single A:T site. However, when the response of this target to ENU was evaluated in spleen (10) , it produced only half the fold-increase of the lacI transgene (11) when normalized to the Hprt response, and was not even signiˆcant. The poor response was attributed to recovery of mutationsˆxed in the bacterial part of the assay. Consequently, single burst analysis was devel-oped for FX174 for distinguishing mutationˆxed in the mouse from thatˆxed in bacteria (12) (13) (14) . Single burst analysis did reduce the spontaneous MF in spleen approximately 3-fold (12) compared to the earlier study (10) and did double the fold-increase in response to ENU. However, the single burst study measured mutations 8 mo after ENU treatment in order to test the system under conditions di‹cult to detect a diŠerence in MF. Therefore, a direct comparison to either the FX174 (10) or lacI study (11) , each done 3 wk after treatment, was not possible. A di‹culty with interpreting single burst analysis for the reversion assay was that small bursts just above a conservative cut-oŠ value of 30 PFUs per aliquot could not be conˆrmed as in vivo by sequencing multiple mutant plaques from the same aliquot: recovering the same mutation repeatedly from a single target site would not argue strongly that they were siblings of the same burst.
Concurrently with the development of the single burst method we developed two other research tools for the FX174 mouse: 1) a transgenic cell line (PX-2) established from embryonic tissue of a homozygous Malling mouse by transformation with the SV40 large tumor (T)-antigen (15) and 2) a forward mutational assay for the FX174 vector (16) . The cell line enabled us to continue development of the assay without further animal usage and the forward assay provided multiple target sites for each of the six possible base pair substitutions. This assay detects base pair substitution mutation primarily in gene a, although some mutations have also been recovered in gene f (17; Valentine et al., unpublished observations.) and gene c (this study).
The FX174 forward selection method requires functional mutants, providing a smaller number of total target sites than an inactivation assay. Among 25 target sites initially identiˆed (16) only one was within a CpG context, suggesting that this forward assay might be less in‰uenced by methylated cytosine deamination than those using other transgenes. Although detection of only base pair substitution is a limitation of the assay, over 90z of mutations in coding sequences of breast or colon cancer tumors are base pair substitutions (18) .
Having developed a forward mutation assay for FX174, we initiated two studies concurrently: 1) treatment of FX174 mice under the same ENU-treatment protocol as for the lacI gene (11), and 2) evaluation of the response of the cell line to UVB. A preliminary report from theˆrst project indicated that spontaneous MFs would be low in vivo and that there were at least 33 target sites (19) with still only 2 CpG sites (20) .
The second project, reported here, was undertaken to evaluate whether the FX174 transgene would be a suitable and sensitive target for UVB mutagenesis. This was of interest to us because the National Toxicology Program Center for Phototoxicity (USA) has a research program at our institution evaluating the eŠects of sunlight exposure and drugs on skin cancer. Since UVBinduced mutations are primarily base substitutions, CªT transitions at dipyrimidine sites (21) (22) (23) (24) (25) , the FX174 forward mutation system should have been welltailored to detect mutagenesis from this exposure. However, CCªTT tandem mutations and CªT transitions at dipyrimidine sites that are within a CpG context are also characteristic of UVB-induced mutations (26) . As mentioned above, there were only two known CpG sites, but also no known CpC sites. Therefore, we conducted a UVB mutagenesis study in cell culture to evaluate the breadth and sensitivity of the FX174 transgene to UVB.
An additional goal of the cell culture study was the optimization of conditions for single burst analysis for the forward assay. Variability in plating e‹ciency for the forward assay had been recognized in previous studies. Also, the report from the in vivo study (19) indicated that the standard plating density for the reversion assay, used initially in this study, was too high for the forward assay to separate mutationsˆxed in the mouse cell from thoseˆxed in bacteria. An attempt to study the eŠect of plating density on the measured cellular MF had been made with the reversion assay, but no eŠect was seen because of the small number of mutants recovered from a single target site (14) . The present study demonstrates the critical need for optimizing this parameter when using the forward mutation assay.
Materials and Methods
Cell culture: The PX-2 cell line (27) was stored frozen in DMEM high glucose medium (BRL 11965-092; Invitrogen, Carlsbad CA, USA) supplemented with 50z (v/v) heat-inactivated fetal bovine serum (Hyclone, Logan VT, USA) and 11z (v/v) dimethylsulfoxide (DMSO). Cells were cultured in DMEM supplemented with 15z serum, 2 mM L-glutamine (Gibco/BRL 25030-081, 200 mM, 1z v/v), 100 U each penicillin and streptomycin per 500 ml DMEM (Gibco/BRL 15140-122, 1z v/v), and b-mercaptoethanol (0.05 M in PBS, 0.1z v/v) (DMEMsupplemented) (16) .
UV source: The UV source was a UVM-57 lamp (95-0104-01, UVP, Upland, CA, USA) emitting both UVA (320-400 nm) (39.4z) and UVB (280-319 nm) (60.2z), with a minor fraction of UVC (250-280 nm) (0.36z) as determined using an Optronics OL-754 spectroradiometer (Optronics Laboratories, Orlando FL, USA). The dose rate of each portion of the spectrum was 27.5, 42.0, and 0.25 J/m 2 /min for UVA, UVB, and UVC, respectively, at 25 cm from the target cells in the exposure dish. The total dose rate of the UVM lamp was 69.8 J/m 2 /min. All irradiations were performed in a biological hood that provided a sterile environment using circulating air sterilized with HEPAˆlters. No light, other than the UV lamp used for the exposure was used in the hood, and the laboratory was illuminated with a low level of yellow safety lights, which do not transmit UVA or UVB.
UVB exposures and cloning e‹ciencies: Five or six 100-mm plastic culture dishes per dose were seeded with 9.5×10 5 cells on Day 0 in DMEM-supplemented medium. Twenty-four h later, one plate was used to count surviving cells, 2.13×10 5 cells per plate on Day 1. Medium was aspirated and each dish was rinsed with 5 mL PBS (with calcium and magnesium, CM) immediately prior to irradiation. Based on a previous scaling experiment with 6 doses, UVB doses were chosen that were expected to produce relative growth after 72 h of approximately 20, 10, and 5 percent in order to bracket the peak of induced MF: 0, 56, 70, and 84 J/m 2 (0, 80, 100, 120 s). Immediately following irradiation, each dish was rinsed again with PBS CM and covered with 10 mL DMEM-supplemented. At 72 h (Day 4) medium was aspirated and each dish rinsed with 5 mL PBS (calcium and magnesium-free, CMF); 1.0 mL of trypsin (0.05z, Life Technologies, Rockville MD, now Gibco-Invitrogen, Carlsbad, CA) was added to each dish. As the cells detached, each cell suspension was triturated and removed from the plate. Each plate was further rinsed with 5 mL DMEM-supplemented and combined with previous cells from the same dose. The combined cells from each dose were collected by centrifugation and resuspended in 1.1 mL DMEM-supplemented for counting by Coulter counter. The control cells yielded 1.65×10 6 cells/mL (10 mL per plate). Relative growth was measured as the ratio of cell counts for each dose to cell counts for the control culture.
Dilutions of cells from each dose were plated to deliver 200 cells per plate (3 plates each dose) for determining cloning e‹ciency. Cloning e‹ciency was calculated as the ratio of the number of colonies grown after one week to the number of cells seeded.
Relative growth calculations: Growth inhibition data were evaluated using the expression R.G.＝e -kD (28), where: R.G.＝Relative Growth D＝dose (J/m 2 ) k＝inhibition constant (J/m 2 ) -1 , the slope of the exponential growth curve. The equation was derived for the surviving fraction for cells plated immediately after treatment. Here cells were counted 72 h after treatment, so we have called this relative growth, rather than relative survival.
Transgene and mutant recovery: After removal of an aliquot for determining cloning e‹ciency, cells were immediately collected by centrifugation and resuspended in small volumes of PBS to yield 5-10×10 6 cells/mL. One mL aliquots from each dose were distributed in microcentrifuge tubes. The cell suspensions were collected by centrifugation and aspirated; to each cell pellet 1.0 mL ATL buŠer (Qiagen, Valencia, CA) and 100 mL proteinase K (40 mg/mL) (Invitrogen, Carlsbad, CA) were added and DNA extracted as previously described (16) . The control DNA sample had a higher e‹ciency of electroporation (i.e., greater total PFUs recovered per mg-see Results) than the two treated samples and consequently was diluted three-fold with 0.1×TE (1.0 mM Tris, pH 8.0, 0.1 mM EDTA) in order to have input DNA below 1 mg.
Initially, electroporations were conducted using 8 mg DNA distributed as 110 mL aliquots in two 48-well plates (19) , referred to hereafter as high plating density. Subsequently, the same samples were reanalyzed using from 0.4 to 3 mg DNA per electroporation (low plating density). The sample from the lowest UVB dose was not reanalyzed.
During the second set of experiments agar plates for the selective assay were incubated in a larger incubator (Forma Scientiˆc, Marietta, OH) in which 96 plates could be held on two shelves. Previously we had used a desk-top incubator (Thelco, Warwick, RI) that required 8 shelves to hold 96 plates. We found that the temperature variation in this incubator resulted in diŠerent plating e‹ciencies depending on the position in the incubator. The temperature also was raised to 34.19 C for the Forma incubator for better e‹ciency of plating. All of the experiments reported here were done with the same batch of competent cells (gift from H. V. Malling, Research Triangle Park, NC).
Sequencing of mutants: PCR ampliˆcation of various regions of the FX174 genome (29) and cycle sequencing DNA synthesis of subregions were performed from eluates of cored agar plugs as described previously (19) . The primers used for PCR and sequencing are given in Table 1 . All aliquots from the control and the 70 J/m 2 UVB dose with plaque counts AE80 had mutants sequenced for the 5? end of gene a. Most of the aliquots from the highest UVB dose, 84 J/m 2 , also had sequencing done in gene a. If no mutation was found for most of the isolates from a single aliquot using primer 4602R, portions of gene f were sequenced for some mutants as indicated (Results).
Deˆnition of plating density: For single burst analysis, each electroporated sample is divided into many aliquots before viral growth is allowed in order to separate the viral progeny of individual FX174 molecules in diŠerent bacterial cells into diŠerent aliquots (12) (13) (14) . We deˆne plating density as the average number of nonmutant PFUs per aliquot (each plated on a separate 100-mm agar plate). Plating density was calculated as the ratio of the total PFUs recovered for an electroporation to the total number of aliquots for that 
, e, j 1146L-CGCAATGGAGAAAGACGGAGAG * For``upper'' primers the name ends in``U'' and the number is the genomic nucleotide number of the 5? nucleotide of the primer; for the``lower'' primers, the name ends in``L'' and the number is the genomic nucleotide number of the 3? nucleotide of the primer. Genomic nucleotide numbering is from (30), now GenBank No. J02482. † For``reverse'' primers, the name ends in``R'' and the number is the genomic nucleotide number of the 3? nucleotide of the primer; for`f orward'' primers, the name ends in``F'' and the number is the genomic nucleotide number of the 5? nucleotide of the primer. ‡ Used initially; subsequently replaced by 4602R because it produced more product and included more of gene a. electroporation. The high density electroporations (above) had 81-96 aliquots; all the low density electroporations had 96 aliquots.``Nonmutant'' refers to the target sites recoverable in this forward assay since all transgenic FX174 vector molecules are mutant at the am3 site in gene e (1). MF calculations: MFs were calculated for single burst analysis by the method of PFUs as described previously (19) . MFs corrected for the results of DNA sequencing were calculated by eliminating the plaque counts from those aliquots with mixed bursts from the summation of total mutant PFUs. An aliquot had mixed bursts when no single mutation accounted for AE50z of the mutants sequenced.
Trend analysis and other statistical tests: Dose trends were estimated by Poisson regression as previously reported in Valentine et al. (16) . This method uses a Poisson regression with an oŠset, the logarithm of the total PFUs, and assumes a variance that is proportional to the Poisson mean, i.e., over-dispersed Poisson. Because the average MF for the highest UVB dose was lower than the next highest dose, our analysis estimated the trend from the sham control and the dose with the greatest response to UVB (70 J/m 2 , 100 s exposure). The lack-of-ˆt of the highest UVB dose (and lowest for high density experiments) relative to this trend was then evaluated for statistical signiˆcance and conˆdence limits.
Signiˆcant diŠerences between mutant spectra were evaluated by the Monte Carlo statistical program of Cariello et al. (30) . P-values for frequencies of double mutations were calculated by the chi-squared test as indicated.
Results
Spectrum of UV lamp: Figure 1 shows the emission spectrum of the UV source. The lamp delivered approximately 50z more UVB than UVA irradiation (60.2z and 39.4z, respectively). The standard erythemal dose (SED) for each portion of the UV spectrum was calculated by multiplying the irradiance at each wavelength by the human erythemal action spectrum (31) . The summed weighted energy of the UVM-57 lamp was 2.71×10 -3 SED/s, with the following weighted Plating density and eŠect on MF: The average plating density of the high density electroporations was 10.85±4.7×10 5 per plate (not shown) compared to 4.2±2.6×10 5 for the low density electroporations (Table 2 ). Figure 2 shows MFs and relative growth as a function of dose at both high and low plating densities for a cut-oŠ of AE80 mutant PFUs. Lowering the plating density an average of 2.6-fold reduced the average spontaneous MF 4-fold (from 0.52 to 0.11×10 -5 ), but did not lower the MFs for UVB treated cells. For the low plating density experiments, plating density was proportional to the DNA input for the control sample (Table 2, R＝0.92).
E‹ciency of electroporation: The e‹ciency of electroporation is re‰ected in the number of genomes recovered per mg DNA (Table 2 ). This can be converted to the percent genomes recovered assuming that a single-copy gene has 3×10 5 copies per mg and that the homozygous FX174 cell line has 50 transgenes per chromosome (1), for an expected 1.5×10 7 genomes per mg. The highest electroporation e‹ciency was thereby found for the control sample, 2z; DNA from the 70 and 84 J/m 2 doses had average electroporation e‹ciences of 0.5z and 1.0z, respectively.
Dependence of MF, fold-increase, and signiˆcance level on plaque count cut-oŠ: MFs, fold-increases, and signiˆcance levels for the response to UVB at 70 J/m 2 were calculated for diŠerent minimum plaque counts per aliquot (cut-oŠs) for mutationˆxed in the mouse cell at low plating density (Fig. 3A-C) .
-3 at all cut-oŠs and the maximum logarithmic fold increase was 3.0 (20-fold arithmetic) (not shown).
Sequencing of mutants and correction of MFs for mixed bursts: Multiple viral plaques from individual aliquots with AE80 mutant PFUs from the low plating density set of electroporations were sequenced for the purpose of conˆrming that multiple plaques had the same mutation (ˆxed in the mouse cell) and for the purpose of producing mutant spectra of mouse cell mutations (below). Sequencing was done for every aliquot with plaque counts 80 and higher from the 70 J/m 2 dose and for most of those aliquots at the 84 J/m 2 dose. The cut-oŠ of 80 was used based on previous results with mouse splenic lymphocytes (19) indicating Table IV , but the second entry of 4019TªG in Table III of that publication should have been this mutation, 4019TªA. ¶ Mutation not previously reported; 4413CªT independent since also found alone (plaque count 94). See Table 5 . **Substitution not previously reported, but target site does have another reported mutation. See Table 4 . † † Mutation not previously reported; 4418GªT also found alone (plaque count 26). See Table 4 . ‡ ‡ New independent mutation; previously isolated with 4225AªG (20) .
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Carrie R. Valentine et al. that this cut-oŠ would eliminate mixed bursts. However, since aliquots with plaque counts of 135, 94, and 84 were shown to contain mixed bursts after sequencing (Table 3) , these aliquots were eliminated from MF calculations in Table 2 and the mutations were not included in mutant spectra (below). All of these three aliquots occurred from the electroporation with the highest plating density (3.86×10 5 PFUs/aliquot) among the 70 J/m 2 electroporations (Table 2 ) and were considered to be composed of multiple bursts of mutationsˆxed in the electroporated bacteria resulting from the higher plating density. Since all aliquots with AE80 mutant plaques had been sequenced for the control and 70 J/m 2 dose (the dose of greatest response to UVB), an accurate correction of MF for mixed bursts could be made for these doses at this cut-oŠ. Also at this cut-oŠ, the fold increase reached a plateau and the signiˆcance level was at its 
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lowest between 50 and 100 PFUs (Fig. 3C) . Therefore, a cut-oŠ of AE80 mutant PFUs per aliquot with AE50z of sequenced plaques from each aliquot having the same mutation, was used as the criteria for identifying mutationsˆxed in the mouse cell.
MFs for embryonic mouse cell line PX-2 corrected for mixed bursts: Multiple cultures exposed to each dose of UVB were pooled before the extraction of DNA in order to provide uniform samples for the evaluation of the reproducibility of the assay. Therefore, MFs were calculated both by averages based on the electroporation and by pooling results for each dose (Table 2) . Conˆdence intervals and signiˆcance levels for the estimated spontaneous and UVB-induced MFs (and fold increase) were based on the pooled MFs by trend analysis. The MF at the highest dose (84 J/m 2 ) was signiˆcantly lower than the dose response trend (pº0.003), although it was not signiˆcantly lower than the next lower dose (70 J/m 2 ) (pº0.08). No clonal correction was applied to MFs based on sequencing results (below) for the same reason none was made for the cII gene in cell culture (32) , which also has multiple identical mutations identiˆed at speciˆc sites in response to UVB irradiation. As for the cII study, only a minute fraction of mutants were rescued after a limited number of cell divisions (a maximum of 3z of the DNA recovered for each dose was electroporated and the e‹ciency of electroporation was 0.5-2.0z). Therefore, we consider that MFs are also mutation frequencies.
Mutations identiˆed by FX174 forward assay: Table 3 shows the mutations found from multiple plaques sequenced from individual aliquots. Plaque counts are entered for all aliquots used for calculating MFs even if not sequenced (84 J/m 2 dose). The total number of FX174 genomes screened was 9.5×10 5 for UVB-irradiated samples and 17.6×10 5 for the control sample (Table 2) . A few selected aliquots from the control sample containing less than 80 PFUs were chosen for sequencing because there were so few aliquots with higher plaque counts.
Single base substitutions identiˆed in Table 3 that have not been previously reported for the FX174 forward assay are listed separately in Supplementary  Table S1 (see online supplemental Table S1 at http:// 
*Mutation was judgedˆxed in the mouse cell if it accounted for 50z or more of plaques sequenced from an aliquot with AE80 total mutant plaques. † Total number of mutant plques for aliquot containing mutation, Table 3 . ‡ Mutated base is in bold italic; codon is underlined. § New independent target site. ¿ New target site, but not independent mutation. ¶ New target site, independent elsewhere; for 4413CªT see``No. plaques in aliquot'', 94, Table 3 ; for 4418GªT see no. of plaques, 26. **New combination of previously reported mutations. † † The last mutation is considered bacterial in origin since it occurred in only one sequenced plaque. ‡ ‡ Last mutation is a new target site, but is not an independent mutation. § § Combination reported previously (19) . ¿¿ New mutation, but not independent.
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www.fda.gov/nctr/science/divisions/documents/ genreptox  docs.htm). All but one (4467GªC) identied new target sites; however, only one of these wasˆx-ed in a mouse cell and induced by UVB (4443CªT). One burst of mutants with a mutation in gene f (1422TªC) was considered to beˆxed in the electroporated bacteria because it was not the predominant burst in the aliquot. A new target site with a CpG context was identiˆed, 4230CªG, but occurred singly and was considered a bacterial mutant. This discovery brought the total number of known CpG target sites to 3 for the FX174 forward mutational assay. Double or triple mutations identiˆed in Table 3 are also listed separately in Table 4 . All of the 4 adjacent multiple mutations were UVB-induced mutationsˆxed in the mouse cell. However, among the non-adjacent multiple mutations only 3 out of 11 wereˆxed in the mouse. Half of the multiple mutants notˆxed in the mouse cells had acquired a secondary (or tertiary) mutation in E. coli in addition to a mouse mutation (aliquots with plaque counts of 189, 516, 239, 104). Double mutants for which at least the second mutation was attributed to E. coli were separated by 67 to 383 base pairs. Non-tandem double mutantsˆxed in the mouse cell were separated by 1 or 36 bases. The adjacent triple mutation, 228-230GGAªAAG, identiˆed not only a target site for CCªTT mutation (considered one site), but also a new gene, c, as a target for the forward assay.
With these additions (Tables 1S, 4 ), the number of reported target sites for the FX174 forward assay totaled 44. However, concurrent work in splenic lymphocytes has brought the total number of known target sites for single base pair substitution to 55 [not shown, Valentine et al., unpublished observations].
Spectra of mutationsˆxed in the mouse cell: The spectra of mouse mutations are shown in Table 5 and summarized in Table 6 . Of the three diŠerent mutations isolated from the control cells, one had a CªT mutation at a CpG site. Twenty percent of the UVB-induced mouse mutations were multiple base pair substitutions, four tandem and three non-tandem. The mutations occurring in the control sample were subtracted from the combined UVB-treated spectrum to produce the UVB-induced spectrum. Mouse cell mutations identiˆed from UVB-treated cells occurred at 22 diŠerent sites and all but one (4008TªA) were dipyrimidine sites. This one exception occurred in an ApTpG context. The most frequently occurring mutation was 4156CªT, and resided in a string of 7 pyrimidines. This mutation occurred both singly and within double mutations, both adjacent and separate. Two sites in the spectrum from UVB-treated cells included a CªT mutation at a CpG dinucleotide, one of which (4425CªT) was isolated 4 times. The second mutation at a CpG site (4162GªA) was at the end of the 7-pyrimidine string (above), and was isolated once from UVB-treated cells and once from control cells.
Only four of the six possible substitutions were recovered in this study, although target sites exist for all. Over 80z of the UVB-induced transitions were G:CªA:T transitions, but less than 15z were this transition within a CpG site. The preference for dipyrymidine context was TpC:CpTÀCpC. Although one-third of the dipyrimidine contexts included CpT, less than 10z had this as the only dipyrimidine context.
Discussion
Spectrum of UV lamp: Although UVA contributed 40z of the irradiation of the lamp, UVB is 5×10 4 times more mutagenic than UVA to the Aprt gene in CHO cells (34) . Therefore, the contribution of the UVA irradiation to mutant induction was considered to be negligible. Ultraviolet C irradiation at 254 nm is approximately 20 times more mutagenic to the Aprt gene in CHO cells than UVB À290 nm (35, 34) . However, the irradiance below 260 nm was 0.00010z (0.00043z weighted) of the total irradiance of the lamp, so the contribution of UVC to mutant induction also was considered negligible. If the mutagenicity action spectrum is similar to the human erythema action spectrum, 98z of the mutagenic response resulted from UVB irradiation.
Experimental design of UVB dosing: Combining all culture plates from a given dose to provide uniform samples was particularly useful since the samples were analyzed twice with diŠerent plating densities. The uniformity of the DNA samples allowed us to recognize that positional and seasonal temperature variation in the incubator was an important factor aŠecting e‹cien- Table 6 . † Control spectra subtracted from UVB spectra, Table 6 . ‡ Double (and triple) mutants all contained at least one G:CªA:T mutation, which were all categorized as primary mutations. Secondary mutations were substitutions other than G:CªA:T found in the multiple mutants. § Multiple mutations are included in the totals above for each mutation type as in note ‡ . ¿ Total is higher than for G:CªA:T above because two additional contexts were included from double mutants.
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cy of plating on the selective strain, which may have been the result of the cold sensitive marker (cs70) in the FX174 genome. This was corrected by using a larger incubator where all plates could be held on 2 shelves and by raising the set temperature slightly from 339to 34.19 C. Plating density: Reducing the plating density improved the UVB response signiˆcantly because it lowered the spontaneous MF. This was accomplished by separating bursts of mutationˆxed in E. coli into separate aliquots. Although multiple E. coli bursts must have occurred in the UVB-treated samples also, the relative proportion to genuine mouse mutations was much greater for the control cells where the spontaneous frequency was low. Also, lowering the density may have separated some mouse cell mutations into separate aliquots, thus keeping the UVB-treated MF high.
Sensitivity of UVB-induced mutant detection in the PX-2 mouse cell line: The response of the FX174 forward mutation assay is compared to that of the cII and lacI transgenes in cell culture normalized for the number of nucleotide target sites for each transgene and for the UVB dose in Table 7 . The normalized, UVBinduced MFs were similar for FX174 and cII, which was 3-fold higher than for lacI. However, the normalized spontaneous MF for FX174 was 9-fold lower than for lacI and 16-fold lower than for cII. Assuming that the variance of the cII frequency was ±1.5×10 -5 [read from Fig. 4a (32) ; mean, 6×10
-5 ] with n＝4, the standard errors on both normalized MFs did not overlap (cII lower bound, 0.03×10 -5 compared to FX174 upper bound, 0.015×10 -5 ), which indicated that the normalized FX174 MF was signiˆcantly lower (pº0.05).
The spontaneous MF per nucleotide reported here for the FX174 embryonic cell line PX-2, 3×10 -8 (Table 7) , was comparable to that of spontaneous germline mutation in human disease genes, which have an average mutation rate of 1. Mutant spectra: The preponderance of CªT mutation at dipyrimidine sites seen here, particularly in the 3? position of the TpC pyrimidine pair, is typical for UVB mutagenesis in cell culture of rodent and human cells (25, 32, 34, (40) (41) (42) as well as rodent epidermis (21, 23, 24) . The signature mutation for UVB, CCªTT (43), was also found. The single G:CªA:T mutation at another CpC target (4443CªT, Tables 1S, 5) might have identiˆed a second CCªTT target site, but the double substitution would replace proline with phenylalanine rather than serine and may not be recoverable. The previous lack of CpC targets may re‰ect that ENU was the only mutagen analyzed previously by the forward assay and indicates that the mutation spectrum is not saturated (44) . Apparently because these two were the only CpC target sites, the CpC context was the least frequent, in contrast to results with the lacZ transgene, in which CpT was the least common (24, 45) . Double mutations are also characteristic of UVB mutagenesis in CHO cells (34) (15z for both types: (16, 19, 20) and unpublished data.
UVB Spectrum in FX174
tandem-5/74 compared to 0/86, pº0.02; non-tandem -6/74 compared to 1/86, p＝0.04, our calculations by chi squared). Non-tandem double mutations separated by a single base also have been observed in nucleotide excision repair-deˆcient mice exposed to UVB (39, 45, 46) and a triplet context for UVB mutation has been suggested (39, 45) . Therefore, mutations in the FX174 transgenes re‰ected well the special characteristics of UVB-induced mutation.
Even though FX174 has only 3 known CpG targets (this study) compared to 22 for the cII gene (47), the percentage of mutants from UVB-treated samples recovered at CpG sites was comparable for both transgenes [14z of all UVB-treated mutants for FX174 compared to 8z for cII (32), our tabulation]. Therefore, the transgenic FX174 forward mutation assay has su‹ciently few CpG targets to achieve a low spontaneous MF, yet enough appropriate CpG targets to respond well to UVB irradiation. This result now recommends testing of the response of the FX174 transgenes to UVB in mouse epidermis.
Gene c as a target gene: For theˆrst time, a mutation in gene c of FX174 has been recovered from the forward mutation assay for this bacterial virus (16, 17, 19, 20) . Although not anticipated, Hayashi (48, p. 35) has speculated that the gene c product``might interact with the rep protein in the RFII-gpA-rep protein complex''. Since mutations in genes a and f are recovered based on interaction with a mutant rep gene of the E. coli selective strain in this complex (16, 17) , interaction of the gene c product with the RFII DNAsynthesizing intermediate could be expected to compensate for the mutant host protein. Since we occasionally isolate mutants with no mutation in the 5? terminus of gene a, but have never sequenced in another gene other than f until this study, these mutations may be more frequent than we can now document.
Conclusions:
The relative paucity of CpG or CpC target sites for the FX174 forward mutational assay did not prevent a robust, characteristic response to UVB for the mouse embryonic cell line PX-2. Further, assay conditions were standardized and plating densities used that allowed a new, low estimate of spontaneous MF for this cell line, comparable to that of the human germline. The FX174 transgene responded as well as the cII transgene in cell culture for induced MF per target site per dose of UVB and its spontaneous MF was an order of magnitude lower.
A primary reason for developing the FX174 forward mutation assay was to reduce spontaneous mutation at CpG sites that contributes to high background mutation. The present results indicate that we have accomplished this goal in cell culture without eliminating the detection of mutation at CpG sites. The next goal is to evaluate this mutation assay in mouse skin.
